Screener
Generate Biomedicines, Inc. GENB PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Restricted cash and cash equivalents (VIE) | — | 339 |
| Prepaid expenses and other current assets | 12,838 | 12,528 |
| Total current assets | 470,253 | 234,365 |
| Property and equipment, net | 27,305 | 29,151 |
| Operating lease right-of-use assets | 55,074 | 59,860 |
| Other assets | 9,058 | 6,806 |
| Total assets | $561,690 | $330,182 |
| Liabilities, convertible preferred stock, non-controlling interest and stockholders’ deficit |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s PP&E (net)?
- Generate Biomedicines, Inc. (GENB) reported PP&E (net) of $27.31M in Q2 2026.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Generate Biomedicines, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude